Regenxbio (RGNX) Announces Proposed Public Offering of Common Stock

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $125,000,000 of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. In addition, REGENXBIO intends to grant the underwriters a 30-day option to purchase additional common shares in an amount of up to 15% of the number of common shares sold in connection with the offering.

Morgan Stanley, Goldman Sachs & Co. LLC, Barclays and Stifel are acting as joint book-running managers of the offering.

You May Also Be Interested In

• Stifel Starts Almonty Industries (ALM) at Buy
• Glucotrack prices $3.1M public offering at $2.04 per share
• Goldman Sachs Reiterates Buy Rating on Five Below (FIVE)